2. Academic Validation
  3. Enhancing the Oral Bioavailability of a Poorly Soluble Pan-CK2 Kinase Inhibitor: Leveraging a Phosphate Prodrug Strategy to Overcome Dissolution-Limited Absorption and Improve Systemic Exposure during Dose Escalation

Enhancing the Oral Bioavailability of a Poorly Soluble Pan-CK2 Kinase Inhibitor: Leveraging a Phosphate Prodrug Strategy to Overcome Dissolution-Limited Absorption and Improve Systemic Exposure during Dose Escalation

  • J Med Chem. 2026 Jan 22;69(2):1641-1660. doi: 10.1021/acs.jmedchem.5c03141.
Murugaiah A M Subbaiah 1,  Naveen Manjunath 1,  Thangeswaran Ramar 1,  Mathiazhagan Annadurai 1,  Naveen Kumar Dhondi 1,  Tarun Sharma 2,  Sheelendra Singh 2,  Megha Thakur 2,  Priyadeep Bhutani 2,  Shahe Mahammad 3,  Srinivas Kasibhatla 1,  Sridhar Desikan 3,  Kurt Zimmermann 4,  Xiaopeng Sang 4,  Gerry Everlof 5,  Mary Obermeier 5,  Aberra Fura 5,  Ashok V Purandare 4
Affiliations

Affiliations

  • 1 Department of Medicinal Chemistry (Prodrug Group), Discovery & Development Sciences, Biocon-Bristol Myers Squibb Research and Development Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India.
  • 2 Department of Pharmaceutical Candidate Optimization, Discovery & Development Sciences, Biocon-Bristol Myers Squibb Research and Development Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India.
  • 3 Department of Biopharmaceutics, Discovery & Development Sciences, Biocon-Bristol Myers Squibb Research and Development Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India.
  • 4 Department of Medicinal Chemistry, Discovery & Development Sciences, Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States.
  • 5 Department of Pharmaceutical Candidate Optimization, Discovery & Development Sciences, Bristol Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States.
PMID: 41499183 DOI: 10.1021/acs.jmedchem.5c03141
Abstract

BMS-135, a preclinical Casein Kinase 2 (CK2) inhibitor, demonstrated subnanomolar potency, robust cellular antiproliferative activity, and pronounced antitumor efficacy in xenograft models. However, its poor solubility posed significant challenges for oral delivery, leading to low oral bioavailability when administered as a solid suspension. Solution formulations improved exposure at lower doses but failed to support dose escalation, resulting in nonlinear pharmacokinetics and diminished bioavailability at higher doses. To overcome these formulation limitations, this study describes the design and synthesis of direct and linker-enabled phosphate prodrugs, resulting in significantly enhanced solubility and improved oral bioavailability up to 14-fold. PK analyses revealed that systemic exposure was governed by both phosphate cleavage and intermediate hydrolysis rates, with steric factors critically influencing enzymatic activation. These findings support the continued development of BMS-135 as an orally bioavailable Anticancer therapeutic and highlight the strategic utility of phosphate prodrugs for facilitating the oral delivery of poorly soluble kinase inhibitors.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z